Time to THROW THOSE OLD MEDS AWAY? Mood Disorder Research Holds Great Promise

Many millions of patients who suffer from depression and related disorders rely on their doctors for the latest treatments. Unfortunately, what they’re getting aren’t always the latest science-backed solutions, but the same old meds that have been around for decades.

Is it because their doctors don’t have access to more recent data? Is it because they’re discouraged from exploring alternative therapies? Perhaps it’s a combination of factors, but either way, it’s bad for the patients because not everyone responds to traditional antidepressants.

This problem is widespread in the medical community and has led to what researchers are actually calling a “psychiatric crisis.” Tragically, mental health disorders are increasingly contributing not only to suffering on an individual basis, but on a global scale as these disorders continue to take a huge social and economic toll.

There’s hope for those who struggle with mental health conditions, and it’s coming from a largely unexpected source: the psychedelic agent known as ketamine, which has been studied as a treatment for depressive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), alcohol abuse, and suicidal thoughts.

So far, clinical trials for ketamine as a treatment for depression have yielded positive outcomes for a significant proportion of the observed patients. Thankfully for depression sufferers who can’t or don’t want to use traditional medications, ketamine has recently been fast-tracked by the FDA and Health Canada for research and development related to depressive disorders.

That’s a regulatory green light and a huge win for Champignon Brands (CSE: SHRM, OTC: SHRMF), a company that researches, develops, and markets ketamine-enhanced solutions for a broad array of mental health issues that millions of people are facing today.

It’s a tremendous opportunity both scientifically and fiscally because there’s a $10 billion market for pharmacologic depressive disorder treatments in North America. Even so, more than 75% of people with these disorders are inadequately treated – that’s unacceptable, and it needs to change.

93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.

Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!

Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!


    Fortunately, Champignon is bringing positive change while creating an appealing value proposition for investors. This is a company that’s expanding its reach at an incredible pace – and in an exciting new development, Champignon Brands is extending its ketamine-enhanced treatment solutions to the state of California. Here’s the rundown:

    • Champignon has executed a term sheet with the Wellness Clinic of Orange County Inc., thereby further advancing the company’s North American clinical expansion.
    • Located within the Mission Hospital’s Laguna Beach campus, the Wellness Clinic owns and operates a state-of-the-art ketamine infusion treatment center.
    • This cutting-edge clinic is an authority in ketamine infusion therapy and is actively involved in research and complementary treatment protocols.

    Champignon CEO Dr. Roger McIntyre noted that this event represents a major milestone as the company establishes a “footprint of integrated ketamine centric clinics committed to providing innovative care and therapeutic options to improve the quality of life of patients suffering from chronic disease states that have failed conventional treatments.”

    This could be just the beginning of a series of value-added, community-enhancing actions as Champignon Brands extends not only the company’s market share, but also the range of options for anyone seeking hope in the ongoing battle against depression.

    Best Regards,

    Tom Beck
    Research Partner, PortfolioWealthGlobal.com

    Protect Yourself Now, By Building A Fully-Hedged Financial Fortress!

    Governments Have Amassed ungodly Debt Piles and Have Promised Retirees Unreasonable Amounts of Entitlements, Not In Line with Income Tax Collections. The House of Cards Is Set To Be Worse than 2008! Rising Interest Rates Can Topple The Fiat Monetary Structure, Leaving Investors with Less Than Half of Their Equity Intact!


      Legal Notice:

      This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.

      Never base any decision off of our emails. Portfolio Wealth Global stock profiles are intended to be stock ideas, NOT recommendations. The ideas we present are high risk and you can lose your entire investment, we are not stock pickers, market timers, investment advisers, and you should not base any investment decision off our website, emails, videos, or anything we publish.   Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. Never base any investment decision from information contained in our website or emails or any or our publications. You should know that Gold Standard Media LLC, owned by the same parties as Portfolio Wealth Global LLC, has been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign.  Our report is not intended to be, nor should it be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation to purchase anything. This publication may provide the addresses or contain hyperlinks to websites; we disclaim any responsibility for the content of any such other websites. Please use our site as a place to get ideas. Enjoy our videos and news analysis, but never make an investment decision off of anything we say. Please read our full disclaimer at PortfolioWealthGlobal.com/disclaimer